Genprex (GNPX) Other Accumulated Expenses (2017 - 2026)
Genprex (GNPX) posted quarterly Other Accumulated Expenses of $1.7 million for Q1 2026, up 175.66% year-over-year from $616148.0 in Q1 2025, and up 18.64% quarter-over-quarter from $1.4 million in Q4 2025.
Genprex (GNPX) Other Accumulated Expenses (2017 - 2026) Analysis & Trends
Genprex's Other Accumulated Expenses history runs 10 years deep, the most recent figure standing at $1.7 million for Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 175.66% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 175.66% YoY), while the FY2025 annual figure was $1.4 million, changed 0.12% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $1.7 million, up from $1.4 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $3.2 million in Q3 2023, with the low at $616148.0 in Q1 2025.
- The 5-year median for Other Accumulated Expenses is $1.5 million (2025), against an average of $1.6 million.
- The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses jumped 312.09% in 2022, then sank 70.3% in 2024.
- Genprex's Other Accumulated Expenses stood at $2.4 million in 2022, then decreased by 21.58% to $1.9 million in 2023, then decreased by 22.98% to $1.4 million in 2024, then increased by 0.12% to $1.4 million in 2025, then rose by 18.64% to $1.7 million in 2026.
- Business Quant data shows GNPX's Other Accumulated Expenses at $1.7 million in Q1 2026, $1.4 million in Q4 2025, and $932260.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Genprex | 1.88 Mn | -13.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.70 Mn |
| Dec 31, 2025 | 1.43 Mn |
| Sep 30, 2025 | 932,260.00 |
| Jun 30, 2025 | 1.51 Mn |
| Mar 31, 2025 | 616,148.00 |
| Dec 31, 2024 | 1.43 Mn |
| Sep 30, 2024 | 938,173.00 |
| Jun 30, 2024 | 1.08 Mn |
| Mar 31, 2024 | 1.66 Mn |
| Dec 31, 2023 | 1.86 Mn |
| Sep 30, 2023 | 3.16 Mn |
| Jun 30, 2023 | 2.36 Mn |
| Mar 31, 2023 | 2.62 Mn |
| Dec 31, 2022 | 2.37 Mn |
| Sep 30, 2022 | 1.77 Mn |
| Jun 30, 2022 | 1.47 Mn |
| Mar 31, 2022 | 1.13 Mn |
| Dec 31, 2021 | 612,100.00 |
| Sep 30, 2021 | 569,952.00 |
| Jun 30, 2021 | 677,427.00 |